Lumican: a new inhibitor of matrix metalloproteinase-14 activity.

Abstract

We previously showed that lumican regulates MMP-14 expression. The aim of this study was to compare the effect of lumican and decorin on MMP-14 activity. In contrast to decorin, the glycosylated form of lumican was able to significantly decrease MMP-14 activity in B16F1 melanoma cells. Our results suggest that a direct interaction occurs between lumican and MMP-14. Lumican behaves as a competitive inhibitor which leads to a complete blocking of the activity of MMP-14. It binds to the catalytic domain of MMP-14 with moderate affinity (KD∼275 nM). Lumican may protect collagen against MMP-14 proteolysis, thus influencing cell-matrix interaction in tumor progression.

• Authors: Katarzyna Pietraszek, Aurore Chatron-Colliet, Stéphane Brézillon, Corinne Perreau, Anna Jakubiak-Augustyn, Hubert Krotkiewski, François-Xavier Maquart, Yanusz Wegrowski
• Journal: FEBS letters (FEBS Lett) Vol. 588 Issue 23 Pg. 4319-24 (Nov 28 2014) ISSN: 1873-3468 [Electronic] England
• PMID: 25304424 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Chemical References

• Chondroitin Sulfate Proteoglycans
• LUM protein, human
• Lum protein, mouse
• Lumican
• Matrix Metalloproteinase Inhibitors
• Collagen
• Keratan Sulfate
• MMP14 protein, human
• Matrix Metalloproteinase 14

Topics

• Animals
• Binding, Competitive
• Cell Line, Tumor
• Chondroitin Sulfate Proteoglycans (metabolism, pharmacology)
• Collagen (metabolism)
• Humans
• Keratan Sulfate (metabolism, pharmacology)
• Lumican
• Matrix Metalloproteinase 14 (metabolism)
• Matrix Metalloproteinase Inhibitors (metabolism, pharmacology)
• Mice
• Proteolysis (drug effects)